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ABSTRAK 
 
Rekombinan EPO manusia (rHuEPO), sebuah tiruan EPO endogen disalahgunakan oleh 
atlet dengan meluas sebagai penambah prestasi melalui satu fenomena yang dikenali 
sebagai pendopan. Kaedah pengesanan semasa penggunaan rHuEPO adalah melalui 
‘isoelectric-focusing (IEF) double-immunoblotting, Sarcosyl-PAGE (SAR PAGE) dan 
lateral flow test’, iaitu pendekatan yang menggunakan antibodi yang dipanggil antibodi 
anti-EPO. Aptamers yang berasaskan asid nukleik berpotensi boleh mengurangkan 
kelemahan yang wujud dalam antibodi anti-EPO. Dalam kajian ini, aptamer RNA yang 
dihasilkan sebelum ini yang digelar sebagai REPORA-6 aptamer RNA telah digunakan 
untuk mengesan EPO. Objektif kajian ini adalah untuk menerima pakai REPORA-6 
aptamer RNA dalam sebuah penapis filter membran berasaskan membahagi berserta 
dengan cerakin transkripsi terbalik dalam mengesan EPO. REPORA-6 RNA aptamer 
telah dicampurkan dengan Epoetin-alpha (EPO-α) sebelum penapisan melalui membran 
yang bersaiz 0.45 µm dengan bantuan daripada sedutan vakum. EPO-terikat aptamer 
RNA, yang berada pada permukaan membran telah dipulihkan semula dengan 
menggunakan urea, disusuli dengan etanol pemendakan. Transkripsi terbalik telah 
dijalankan diikuti dengan PCR sehingga muncul jaluran saiz yang betul (99 bp). Had 
pengesanan (LOD) ditakrifkan sebagai jumlah EPO yang menyebabkan jaluran PCR 
dengan intensitinya lebih tinggi daripada pengikat khusus latar belakang daripada 
membran yang paling rendah (0 nM EPO). Secara teknikal, EPO telah dimasukkan ke 
dalam serum dan air kencing untuk meniru contoh klinikal yang sebenar. LOD yang 
dicapai untuk EPO dan bagi EPO yang dimasukkan ke dalam serum adalah 18.38 nM. 
Bagi EPO yang dimasukkan ke dalam air kencing, LOD tidak dapat ditentukan kerana 
degradasi aptamer RNA yang mencadangkan pengubahsuain kimia untuk meningkatkan 
xi 
 
kestabilannya. Walaupun begitu, membran berasaskan membahagi berserta dengan 
cerakin transkripsi terbalik berasaskan aptamer berpotensi dalam diagnostik pengesanan 
EPO.  
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ABSTRACT 
 
Recombinant human EPO (rHuEPO), a mimetic of endogenous EPO is widely misused 
by athletes as a performance enhancer, a phenomenon known as doping. Current 
methods of detecting rHuEPO doping are via isoelectric-focusing (IEF)-double-
immunoblotting, Sarcosyl-PAGE (SAR PAGE) and lateral flow test, which are 
antibody-based approach using anti-EPO antibody. The caveats associated with anti-
EPO antibodies have spurred the interest to adopt an alternative molecular recognition 
element (MRE) in detecting EPO. Aptamers, as the nucleic acid-based MREs can 
potentially alleviate the disadvantages inherent in anti-EPO antibodies. Previously, 
REPORA-6 RNA aptamer was isolated against EPO with the dissociation constant of 
25 nM. The objective of the study is to adopt REPORA-6 RNA aptamer in a 
nitrocellulose filter membrane-based partitioning coupled with reverse transcription 
assay in detecting EPO. REPORA-6 RNA aptamer was incubated with Epoetin-alpha 
(EPO-α) before filtration through the 0.45 μm nitrocellulose membrane with the aid of 
vacuum suction. EPO-bound RNA aptamers, retained on the surface of the membrane 
was recovered using urea, ensued by ethanol precipitation. Reverse transcription was 
carried out followed by PCR amplification till the band of the correct size appears (99 
bp). Limit of detection (LOD) was defined as the lowest amount of EPO that results in 
the PCR band with the intensity higher than the background non-specific binders of the 
nitrocellulose membrane (0 nM of EPO). LOD was also approximated for the EPO 
spiked into human serum and urine to mimic the actual clinical samples. LOD achieved 
for EPO and for the EPO spiked into serum were 18.38 nM. For EPO spiked into urine, 
LOD could not be determined due to the degradation of the RNA aptamer, which 
suggests chemical modification for the enhanced stability. Despite this, nitrocellulose 
xiii 
 
filter membrane based partitioning-reverse transcription based on REPORA-6 RNA 
aptamer could be a potential aptamer-based assay in the diagnostic detection of EPO. 
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CHAPTER 1: 
INTRODUCTION 
 
1.1 Endogenous and Recombinant Erythropoietin (EPO) 
 
 Human erythropoietin (HuEPO) is a 30.4 kDa glycoprotein that stimulate the 
proliferation and differentiation of erythroid progenitor cells into red blood cells 
(Fisher, 2003). EPO gene which is located on chromosome 7 produces EPO, a 
polypeptide which contains 193 amino acids (Manneberg et al., 1994) in kidney (Moore 
& Bellomo, 2011). EPO gene is activated by a stimulating factor called tissue hypoxia 
under stress condition in which more oxygen is needed to be supplied to the blood and 
artery (Figure 1.1) (Maiese et al., 2004). In conditions like bleeding or haemolysis, 
kidney and liver cells capable of sensing the tissue hypoxia and eventually synthesise 
and secrete EPO into plasma (Thorling & Erslev, 1968).  
 
The advancement of recombinant DNA technology allow researchers to isolate 
and incorporate the EPO-encoding genes into bacterial plasmid which was then 
transformed into E.coli host. Hence, the born of recombinant HuEPO (rHuEPO) is the 
first cloned hematopoietic growth factor (Jacobs et al., 1985). However, the expression 
of rHuEPO in mammalian cells such as ovarian cells of chinese hamster (CHO) or 
kidney cells from hamster cub (BHK) is preferred due to the presence of disulphide 
bindings and glycosylation which can only be obtained in mammalian cell culture 
system (Choi et al., 1996). Recombinant HuEPO are later on available in many forms 
such as EPO alpha, EPO beta and EPO omega which is primarily use for therapeutic 
purposes. When compared to endogenous EPO, rHuEPO has similar peptide sequence 
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with different sugar chains due to the lack of specific glucose transferase enzymes 
which function in carrying out enzymatic reactions after the formation of 
polysaccharides (Storring et al., 1998; V. Skibeli et al., 2001). 
 
 
 
 
 
Figure Source: (Citartan et al., 2015) 
Figure 1.1: The interaction between tissue hypoxia and EPO. Under hypoxia (low 
oxygen level), HIF-1α forms a heterodimer with HIF-1β to generate HIF-1 which acts 
as the activator that binds to hypoxia response element (HRE). The binding of HIF-1 
eventually increase the expression of EPO mRNA and formation of EPO. While under 
normal oxygen level, HIF-1α will be degraded by proteasome.  
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1.2 Usage of Recombinant Human EPO in Blood Doping 
 
 The capability of rHuEPO to increase haemoglobin level without any 
complications and difficulties such as administration without medical supervision unlike 
other drugs caught the attention of athletes to resort rHuEPO in increasing their stamina 
illegally (Bento et al., 2003). This process is known as doping and many athletes are 
involved in doping ever since EPO is available in the market. The most publicised 
rHuEPO doping happened in 1998 during the “Tour de France” when rHuEPO ampules 
were discovered from the participating cyclists (G. Skibeli et al., 1998; Zorpette, 2000). 
Recovery of drugs from the truck of main participating team to competitor’s lodgings in 
this event showed the significant and adverse use of rHuEPO in sports (Lancet, 1998; 
Jarvis, 1999; Zorpette, 2000). The very first fatal case associated with doping occurred 
in 1990s when a professional Dutch cyclist died at rest due to obscure cardiac arrest 
while some of them died while sleeping. These cases reported are among more than 20 
cases occurred during the period of 1987 to 1991 when rHuEPO was first introduced in 
that continent (Thein et al., 1995; Gareau et al., 1996). 
 
The unexplainable fatal cases among healthy athletes are due to the uptake of 
rHuEPO that could place one’s health under risk. This is because the increase in number 
of red blood cells by rHuEPO will eventually increase the blood thickness and reduce 
the cardiac output. In a medical condition called erythrocytic aplasia, athletes might 
develop anti-EPO antibodies that destroy both the endogenous EPO and rHuEPO 
(Casadevall et al., 2002). As a result, the International Olympic Committee (IOC) 
banned the usage of rHuEPO since 1990 after the evidence of using rHuEPO in Calgary 
Winter Games and Seoul Olympic Games in 1988 was obtained. Hence, WADA 
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established the isoelectric-focusing double immunoblotting technique to monitor the 
abuse of rHuEPO among athletes (Bento et al., 2003). 
 
1.3 Direct Detection of EPO Relies on Anti-EPO Antibody 
  
 Direct detection of EPO relies on the interaction between the EPO and its 
molecular recognition element (MRE). The current molecular recognition element used 
for the detection of EPO is monoclonal anti-EPO antibody, MAb AE7A5. This antibody 
is used in a variety of applications such as IEF-double immunoblotting, which is the 
testing method accepted by WADA to detect the illegal use of rHuEPO. Moreover, 
another recent method approved by WADA, Sarcosyl-PAGE (SAR PAGE), which is 
used to monitor the detection of rHuEPO abuse among athletes, also relies on the anti-
EPO antibody. Likewise, Lonnberg et al. (2012) have devised EPO wheat germ 
agglutinin (WGA) Membrane Assisted Isoform ImmunoAssay (MAIIA): a lateral flow 
test for rHuEPO detection that is more sensitive than IEF-double-immunoblotting, 
based on monoclonal anti-EPO antibody. However, non-specific interaction of this 
monoclonal antibody with several proteins including from human, bacterial and yeast 
were reported (Franke & Heid, 2006; Delanghe et al., 2008). This suggests the efforts to 
look into an alternative MRE in order to address the specificity associated with the 
monoclonal anti-EPO antibody.   
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1.4 Aptamers-Coming of Age Molecular Recognition Element 
 
Aptamers or also popularly known as ‘chemical antibodies’ are single stranded 
oligonucleotides that bind targets with high specificity and affinity. The word aptamer is 
derived from Latin word aptus meaning “to fit” (Ellington & Szostak, 1990; Tuerk & 
Gold, 1990). Aptamers bind targets via various interactions such as electrostatic, wan 
der Waal forces or hydrogen bonding. The simple process of in vitro selection known as 
SELEX is used to generate aptamers.  
 
 1.4.1 SELEX 
 
Systemic Evolution of Ligands by Exponential Enrichment (SELEX) technology 
is an in vitro selection technique developed by Tuerk and Gold (1990) and Ellington 
and Szostak (1990). This technique is useful in isolating specific binding nucleic acids 
that bind specifically to target from pools of more than 1014 to 1015 different molecules 
(Jayasena, 1999).  
 
The SELEX process begins with the preparation of the degenerate single-
stranded DNA library that contains a random region flanked by a constant primer 
binding region at the 5’ and 3’ of the sequences (Figure 1.2). The library can be used 
directly for incubation with the target in the case of DNA aptamer generation. However 
for RNA aptamer generation, the ssDNA library must be PCR-amplified before 
subjection to in vitro transcription to produce RNA library. Following binding, the 
target-bound nucleic acid molecules are separated from the unbound molecules by 
partitioning method. The bound molecules are recovered and amplified by Polymerase 
6 
 
Chain Reaction (PCR) or Reverse Transcription-PCR (RT-PCR), for DNA aptamer or 
RNA aptamer, respectively. The amplicons from the RT-PCR reaction is used to 
generate RNA molecules for the RNA aptamer generation while ssDNA is derived from 
the PCR product in the case of DNA aptamer generation. These molecules are subjected 
to the subsequent round of SELEX and this process is repeated for 8 to 12 cycles. The 
nucleic acid pool is cloned, sequenced and the putative aptamer identified is verified for 
binding against the target protein (Kim & Gu, 2013).     
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Figure source: (Kim & Gu, 2013) 
Figure 1.2: SELEX technology used in the generation of aptamers. The process 
consists of four main steps – binding, elution, amplification and separation. Once an 
enriched pool of selected nucleic acids is obtained, the nucleic acids are cloned and sent 
for sequencing. Further binding studies will be carried out in order to determine the 
putative aptamer against the target.  
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1.4.2 Advantages of Aptamers over Antibodies 
 
 The unique properties of aptamer make it as an elegant and attractive molecular 
recognition element (MRE) that rival and in some cases surpass antibodies. Aptamers 
can detect wide variety of targets ranging from small molecules to supramolecular 
complexes (Jayasena, 1999; Shamah et al., 2008). This includes proteins, peptides, 
nucleotides, amino acids, antibiotics, low-molecular organic or inorganic compounds, 
and even whole cells. The high specificity of aptamer enable it to differentiate between 
closely related target molecules. For example, aptamers able to discriminate 
theophylline from caffeine which differs by only a methyl group (Jenison et al., 1994) 
and oxytetracycline from tetracycline which differs by only a hydroxyl group (Niazi et 
al., 2008). Firstly, aptamers have a very low dissociation constant (Kd) that can go up to 
picomolar (1×10-12 M) to nanomolar (1×10-9 M) range, which is comparable to the 
binding affinity of antibody against the target antigen. Secondly, aptamers have higher 
thermostability than antibodies. Unlike antibodies, aptamers can resort to its original 
conformations at the room temperature after denaturation at much more higher 
temperature (Jayasena, 1999).  
 
Besides, aptamers can be easily amplified via polymerase chain reaction (PCR) 
unlike antibodies, which requires a biological system for production. Hence, production 
of aptamer is much more cost-saving compared to the antibody. Moreover, since the 
production of aptamer involves in vitro process, there is no need for an in vivo 
immunization. As such, production of aptamers by using a chemical process eliminates 
any batch to batch variations (You et al., 2003). The small size of aptamers which is 
usually less than 20kDa enable it to reach the previously blocked or intracellular targets 
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(Jayasena, 1999). Since aptamers are nucleic acid, it can be easily labelled or modified 
by using reporter molecules, linkers and other functional groups (Luzi et al., 2005) such 
as dyes which acts as a simple means of detection (Jayasena, 1999). These advantages 
show the potentials of aptamers being used in variety of applications thus replacing 
antibodies.  
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1.5 REPORA-6 RNA Aptamer in Detecting EPO 
  
 In the previous study, RNA aptamer termed REPORA-6 specific against EPO 
was generated with a dissociation constant of 25±1 nM (Figure 1.3). This aptamer that 
can act as a ‘universal probe’ against all rHuEPOs/eEPO have been demonstrated to 
have potential in diagnostic and therapeutic applications (Citartan et al., 2014). 
  
 
 
Figure source: (Citartan et al., 2014) 
Figure 1.3: Secondary structure of REPORA-6 RNA aptamer as predicted by mfold 
programme 
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1.6 Objectives 
 
 Though IEF-double immunoblotting is the gold standard approved by WADA, 
this methods suffers from several limitations. First, the usage of anti-EPO antibody is 
expensive. Second, cross-reactivity has been reported by Franke and Heid (2006), in 
which the monoclonal antibody binds non-specifically to a large number of bacterial 
proteins, intracellular and extracellular proteins found in urine. The caveats associated 
with anti-EPO antibodies suggests the adoption of a more amenable molecular 
recognition element (MRE) in detecting rHuEPO.  
 
Owing to the specificity of REPORA-6 RNA aptamer against EPO, this aptamer 
was applied in a novel nitrocellulose filter membrane based partitioning-reverse 
transcription in detecting EPO. The assay developed is envisaged to have a potential for 
the direct detection of EPO. Thus the objectives of study are as follow: 
 
i) To develop a novel nitrocellulose filter membrane based partitioning-
reverse transcription using REPORA-6 RNA aptamer in detecting EPO  
ii) To determine the detection limit of EPO spiked into human serum 
iii) To determine the detection limit of EPO spiked into human urine  
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CHAPTER 2: 
MATERIALS AND METHODS 
 
2.1  Preparation of REPORA-6 RNA Aptamer 
2.1.1 Polymerase Chain Reaction 
 
The ssDNA oligonucleotide used in this study is 5’-
GGGAGAATTCCGACCAGAAGGGTGTTCCGTCGGTGTTAAGTGTAACCTTTCC
TCTCTCCTTCCTCTTCT-3’ while the primers used were the forward primer-5’ AGT 
AAT ACG ACT CAC TAT AGG GGG AGA ATT CCG ACC AGA AG 3’ and reverse 
primer-5’ AGA AGA GGA AGG AGA GAG GAA AGG 3’(Bio Basic Inc., Ontario 
Canada).  
 
PCR amplification was carried out in a 100 µl reaction mixture containing 1X 
PCR buffer (10 mMTris-HCl [pH 8.8], 50 mM KCl, 0.08% [v/v] Nonidet P40) 
(Promega Corporation, Madison, USA), 1.5 mM MgCl2(Promega Corporation, 
Madison, USA), 0.2 mM dNTP (Roche, Basel, Switzerland), 5 U of TaqDNA 
polymerase (Roche, Basel, Switzerland), and 0.6 μM of each primers. The amplification 
was carried out for 10 cycles using the PCR thermocycler (Bio-Rad Laboratories, 
Hercules, USA) with the following parameters; (a) denaturation at 94°C for 60 seconds 
(b) annealing at 55°C for 50 seconds (c) extension at 72°C for 70 seconds and (d) final 
elongation at 72°C for 300 seconds.  
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 2.1.2 Agarose Gel Electrophoresis  
 
Five microliters of the PCR product was mixed with 1 μL of 6X Blue/Orange 
DNA loading dye (10mM Tris-HCl [pH 7.5], 50 mM EDTA [pH 8.0], 0.4% orange G, 
0.03% bromophenol blue, 0.03% xylene cyanol FF, 15% Ficoll® 400) (Promega 
Corporation, Madison, USA) containing 0.5 μg/mL of ethidium bromide (Sigma, St. 
Louis, USA). Gel electrophoresis was then carried on 4% agarose gel (Promega 
Corporation, Madison, USA) with 1X TAE buffer (40 mMTris-acetate, 1mM EDTA) 
using a agarose mini gel apparatus (Bio-Rad Laboratories, Hercules, USA) at 100 V for 
30 minutes followed by visualisation of the gel using Bio-Rad Gel Dol 2000 (Bio-Rad 
Laboratories, Hercules, USA). The size of the PCR product which is 99 bp was 
confirmed with 25 bp DNA ladder (Promega Corporation, Madison, USA). 
 
 2.1.3 Ethanol Precipitation  
 
Ethanol precipitation was carried out throughout the study to concentrate both 
DNA and RNA. Firstly, the concentration of the salt solution was adjusted to 0.3 M by 
the addition of the 1/10 volume of the solution by 3 M sodium acetate (pH 5.2). 
Followed by the addition of 2.5 volume of absolute ethanol (Merck KGaA, Darmstadt, 
Germany) and incubation at -80°C for 15 min. Following centrifugation (Refrigerated 
Centrifuge 5810R, Eppendorf, Hamburg, Germany) at 13,000 x g for 15 min at 4°C, 
supernatant was removed and 1 mL of 70% ethanol was added as a washing step. After 
a brief centrifugation at 13,000 x g for 2 min, supernatant was removed and the pellet 
was air-dried in a vacuum concentrator (Eppendorf, Hamburg, Germany) and dissolved 
in appropriate volume of ddH2O. 
14 
 
2.1.4 In Vitro Transcription and Denaturing Urea Polyacrylamide Gel 
Electrophoresis  
 
Four microliters of the ethanol precipitated PCR product was applied directly for 
an in vitro transcription reaction. In vitro transcription was carried out using 
AmpliScribeTM T7-FlashTM Transcription Kit (Epicentre Technologies Corp, Madison, 
USA). The reaction mixture assembled in 20 μL contains 1X AmpliScribe T7 reaction 
buffer (40 mMTris-HCl [pH 7.5], 6 mM MgCl2, 10 mMNaCl, 2 mM spermidine), 7.5 
mM each of ATP, CTP, UTP, GTP, 10 mM of dithiothreitol (DTT), 20 U of 
AmpliScribeTM T7 Polymerase Flash Enzyme Solution (10 U/μL) and 20 U of 
RiboGuard RNase Inhibitor (40 U/μL). The reaction mixture was incubated at 37°C for 
overnight (Fisher Scientific International, Inc., Hampton, USA).  
 
Following in vitro transcription, treatment with 10 U of RNase-Free DNase I 
(Fermentas, Burlington, Canada) was done at 37°C for 20 min. To stop the reaction, 
equal volume of 2X RNA loading dye (8 M urea, 0.05% bromophenol blue) was 
pipetted into the mixture. The mixture was immediately cooled on ice after heated at 
95°C for 2 min in Thermo Scientific Thermo-Shaker (Thermo Scientific, Waltham, 
USA). The mixture was loaded onto 10%, 7 M denaturing-urea polyacrylamide gel 
followed by electrophoresis in 1X TBE (89 mMTris-borate [pH 8.0], 2 mM EDTA) 
using BioRad Mini-PROTEAN 3 Electrophoresis Cell (Bio-Rad Laboratories, Hercules, 
USA) at 140 V for 1 hour.  
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2.1.5 Purification of Transcribed RNA (Crush and Soak Method) 
 
To purify the in vitro transcribed RNA, a rapid method of small RNA 
purification was established (Citartan et al., 2012b, 2012c). Upon electrophoresis, one 
of the glass plates was removed carefully and the gel was covered with a clean plastic 
wrap. The gel was placed upside down on a flat surface and removed slowly from the 
glass plate with the aid of scalpel. The gel covered with plastic wrap was placed on top 
of the silica coated glass plate (Merck KGaA, Darmstadt, Germany) and visualized by 
using hand-held u.v. light source (UVP, LLC, Upland, USA). Band of interest 
visualized as a single prominent band (under low-intensity u.v. shadowing [254 nm]) on 
the surface of the silica coated glass plate) was excised using a clean razor blade and 
transferred into a sterile 1.5 mL microcentrifuge tube (Eppendorf, Hamburg, Germany). 
The gel slices were then crushed into tiny particles by using 1 mL pipette tip. The 
crushed gel particles was added with 400 μL of ddH2O, heated at 50°C for 30 min, 
followed by the addition of 1 mL of 100% ethanol into the mixture which was then 
shaked vigorously. The mixture was then centrifuged at 13,000 x g for 1 min, followed 
by the collection of the supernatant into a fresh microcentrifuge tube and added with 40 
μL of 3 M NaOAc (pH 5.2). After incubation at -80°C for 15 min and centrifugation (at 
13,000 x g for 15 min at 4°C), supernatant was removed and the pellet was washed with 
1 mL of 70% ethanol. Following a brief centrifugation at 13,000 x g for 2 min, 
supernatant was removed, the pellet was air-dried and dissolved in an appropriate 
volume of ddH2O. Spectrophotometric concentration measurement was carried out 
using nanodrop spectrophotometer (ImplenInc, Westlake Village, USA). 
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2.2  Nitrocellulose Filter Membrane Based Partitioning-Reverse Transcription 
2.2.1 Nitrocellulose Filter Membrane Based Partitioning 
 
REPORA-6 RNA aptamer was prepared as mentioned in Section 2.1. Firstly, 
different concentration of commercially available Epoetin-α (ProSpec-
TanyTechnoGene Ltd, Israel) was prepared by diluting in 1X HEPES-KOH buffer (pH 
7.4). Then 1 µg of REPORA-6 RNA aptamer dissolved in 1X HEPES-KOH buffer was 
denatured at 95°C for 2 mins and let to cool down at RT before adding into the EPO 
protein. The reaction mixture in a volume of 50 µL was incubated for 10 mins at room 
temperature to allow the binding to occur. The RNA protein complexed were filtered 
through a pre-wetted 0.45 µm nitrocellulose membrane filter (Millipore, Billerica, USA) 
which was placed on top of the ‘pop-top’ filter holder (Whatman, Maidstone, UK) with 
the aid of vacuum suction (Figure 2.1) (Vacuubrand, Inc., Wertheim, Germany). The 
membrane was washed using one mL of 1X HEPES-KOH buffer (pH 7.4) to remove 
the unbound molecules while the EPO-bound RNA aptamers retained on the surface of 
the membrane was recovered by heating in 400 µL of 7M urea (Amresco LLC, Cochran 
Rd, USA). This was done by adding 200 µL of 7M urea into the nitrocellulose 
membrane in the sterile 1.5 mL microcentrifuge tube (Eppendorf, Hamburg, Germany). 
The membrane was crumpled using a pipette tip prior heating at 95°C for 2 mins. This 
step was repeated again to recover all the bound RNA aptamers from the membrane. 
The solution containing the bound RNA molecules was added with 4 μL of 
Dr.GenTLETM precipitation carrier (Takara Bio, Japan), 40 μL of 3 M NaOAc (pH 5.2) 
and 1 mL of 100% ethanol. After vigorous shaking, the mixture was centrifuged 
immediately at 13,000 x g for 15 min at 4°C and the supernatant was discarded. The 
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pellet was washed with 70% ethanol and subjected to RT-PCR. For the negative control, 
addition of EPO protein into the 1X HEPES-KOH buffer was omitted.  
 
2.2.2 Reverse Transcription – Polymerase Chain Reaction (RT-PCR)  
 
The recovered RNAs from the above step was reverse-transcribed in 20 μL of a 
reaction mixture containing 1X AMV reverse transcriptase reaction buffer (50 mMTris-
HCl [pH 8.5], 8 mM MgCl2, 30 mMKCl, 1 mM DTT) (Fermentas, Burlington, 
Canada), 1.6 mM dNTPs, 0.4 μM of reverse primer and 10 U of AMV reverse 
transcriptase (Fermentas, Burlington, Canada). The reaction mixture was heated at 95°C 
for 2 min following incubation at RT for 10 min before dNTPs and enzymes were 
added. Reverse transcription reaction was performed at 60°C for 1 hr. First-strand 
cDNA obtained was subjected to PCR amplification until the band of the right size  (99 
bp) appeared. The PCR reactions parameters were as described above (Section 2.1.1).  
 
 2.2.3 Determination of Limit of Detection (LOD)  
  
 In this assay, the limit of detection (LOD) was defined as the lowest 
concentration of EPO that results in the PCR product with the band intensity higher than 
that of 0 nM. The appearance of the PCR product at 0 nM of EPO is due to the non-
specific binding of the aptamers to the nitrocellulose membrane (0 nM). The intensity of 
the band was measured using ImageJ programme (http://rsbweb.nih.gov/ij/).  
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Figure 2.1: Schematic diagram on the principle of nitrocellulose filter membrane based 
partitioning coupled with reverse transcription in detecting EPO. 
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2.3  Serum Preparation and Spiking  
  
 The commercially-purchased human male serum sample (Sigma-Aldrich, St 
Louis, USA) was first diluted in a ratio of 1:1000 using 1X HEPES-KOH buffer (pH 
7.4). The method stated in Section 2.2 was repeated. However a slight modification was 
done to accommodate the spiking step.  Instead of adding the commercial rHuEPO-α 
protein directly into the HEPES-KOH buffer, the EPO protein was first mixed into 
diluted serum and incubated with REPORA-6 RNA aptamer before proceed to the next 
step (Refer to Section 2.2). 
 
2.4 Urine Sample Preparation and spiking 
 
 The urine samples used in this project are always freshly collected in Ideal Care 
specimen container (Ideal Health Care, Kedah, Malaysia) and the time of the day in 
which the samples are collected is not fixed as it does not interfere in any way with the 
experiment. The urine samples obtained were centrifuged at 4000 x g (Kubota 
Centrifugal Machine 3740, Osaka, Japan) for 15 min at room temperature to sediment 
any debris present in the urine. Only the supernatant was collected in a sterile 1.5 mL 
microcentrifuge tube (Eppendorf, Hamburg, Germany) and used in this experiment for 
spiking. The collected supernatant was spiked in a similar fashion as the serum sample 
spiking. 
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2.5  Determination of REPORA-6 RNA Aptamer Stability  
 
Urine samples obtained were centrifuged at 4000 x g (Kubota Centrifugal 
Machine 3740, Osaka, Japan) for 15 min at room temperature to sediment any debris 
present in the urine. Only the supernatant collected in a sterile 1.5 mL microcentrifuge 
tube was added with (1 µg) 800 nM of purified REPORA-6 RNA aptamer in a total 
reaction mixture of 50 µL. At 0 hour (the second EPO was added into the urine), 5 µL 
from the reaction mixture was pipetted into an Eppendorf tube and stored at -20 ºC to 
perform denaturing urea polyacrylamide gel electrophoresis. The procedure above was 
repeated for every 30 minutes, 1 hour, 2 hours and 24 hours at room temperature. 
 
Equivalently, the stability of the RNA aptamer in human serum was also 
determined. However, the commercially-purchased human male serum sample (Sigma-
Aldrich, St Louis, USA) was first diluted in a ratio of 1:1000 using 1X HEPES-KOH 
buffer (pH 7.4) before the addition of REPORA-6 RNA aptamer.  
.  
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CHAPTER 3: 
RESULTS AND DISCUSSION  
 
3.1 In vitro transcription produces intact REPORA-6 RNA aptamer 
 
 REPORA-6 RNA aptamer was derived from the amplicon of the REPORA-6 
oligonucleotide ssDNA. The REPORA-6 RNA transcript was purified via small RNA 
purification method (Citartan et al., 2012b, 2012c) from the urea-denaturing PAGE. The 
purified RNA is stable (Figure 3.1) and is suitable for the direct detection of EPO.  
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Figure 3.1: 5 µL of REPORA-6 RNA aptamer electrophoresed on 4% agarose gel. 
Black arrow indicates RNA transcript.   
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3.2  Formation of REPORA-6 RNA aptamer-EPO complex 
 
 One µg (800 nM) of REPORA-6 RNA aptamer is incubated with EPO of 
different concentrations from 4.59 nM to 588.2 nM. Incubation was carried out in 1X 
HEPES buffer (10 mM HEPES-KOH [pH 7.4], 150 mM NaCl) at room temperature for 
10 minutes. Similar binding parameters which was used previously in the SELEX for 
the isolation of the REPORA-6 RNA aptamer were retained for optimal aptamer-EPO 
complex formation. Similarly, incubation was also carried out with the EPO spiked into 
serum and urine samples. Incubation will result in the formation of the EPO-aptamer 
complex. However, the unbound REPORA-6 RNA aptamers present have to be 
partitioned from the EPO-bound molecules. This is important for accurate quantification 
of the RNA molecules bound to the EPO, as incomplete partitioning may cause false 
positivity. The method that is adopted for separation of the EPO-bound from the 
unbound molecules is the nitrocellulose filter membrane-based partitioning. 
 
3.3 Nitrocellulose filter membrane-based partitioning to separate EPO-bound 
from unbound RNA molecules 
 
 Membrane filtration was developed in 1970s in the early stages of molecular 
biology to study the interaction of protein-nucleic acid complex formation. Initially, this 
method was established to examine RNA-protein interaction (Nirenberg et al., 1965) 
before being introduced to analyse the DNA-protein interaction (Jones & Berg, 1966). 
In this study, following the incubation with the target EPO protein, the unbound 
REPORA-6 RNA aptamer is separated from the bound molecules via 0.45 µm 
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nitrocellulose filter membrane-based partitioning with the aid of vacuum suction. The 
target protein EPO will be retained on the surface of the nitrocellulose filter membrane 
via electrostatic and hydrophobic interactions without losing their binding capacity to 
the aptamers (Helwa & Hoheisel, 2010). Since the REPORA-6 RNA aptamer has a 
higher binding affinity towards EPO, the EPO-aptamer complex will retained on the 
membrane (Figure 3.2).  
 
 The retained REPORA-6 RNA aptamer on the membrane, which is bound to the 
EPO was recovered using urea. Recovery of the bound nucleic acids from the 
membrane can be carried out by heating, changing the ionic strength or pH and also by 
adding denaturing substances like urea, sodium dodecyl sulphate (SDS) or 
ethylenediaminetetraacetic acid (EDTA) (Geiger et al., 1996; Bianchini et al., 2001; 
Stoltenburg et al., 2005). In this study, urea is used as the chaotropic agent as it is 
simple and inexpensive. Heating at 95°C for five minutes causes the urea to impart its 
denaturation property on the EPO protein, thus releasing the RNA molecules. The 
recovered RNA molecules were then ethanol precipitated and subjected to the 
amplification step.  
 
 
 
 
 
  
